NAMS Firefly

Firefly Neuroscience, operating as NAMS Firefly, is a neurotechnology company that emerged from the rebranding of Wavedancer, Inc.

Reviewed by 7wData
Share Email

On this page

Profile

Develops AI-powered neurotechnology software for brain health monitoring and cognitive enhancement.

Firefly Neuroscience, operating as NAMS Firefly, is a neurotechnology company that emerged from the rebranding of Wavedancer, Inc. in 2024. The company focuses on developing AI-driven software solutions for neurological applications, with a particular emphasis on brain health and cognitive performance. Financial reports from Q1 2026 show steady growth, with net sales of SEK 112.2 million (approximately $10.7 million) and operating results of SEK 11.9 million (about $1.1 million), maintaining a 10.6% operating margin.

The company's order book stood at SEK 111.3 million at the end of Q1 2026, indicating stable demand. Firefly has consistently grown its revenue from SEK 302.1 million in 2021 to SEK 503.2 million in 2025, with operating margins improving from 9% to 13% over the same period. The company's cash flow from operations was SEK 15.7 million in Q1 2026, with liquid funds of SEK 95.2 million, suggesting a solid financial position for continued R&D investments. Recent SEC filings in May 2026 indicate ongoing capital-raising activities, including an S-8 employee benefit plan registration and an S-3 shelf registration, signaling potential future growth initiatives or acquisitions.

Track NAMS Firefly and 240+ vendors.

48k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Healthcare providers and hospitals seeking neurological diagnostic tools
  • Research institutions studying brain function and cognitive disorders
  • Corporate wellness programs focusing on employee cognitive performance
  • Government agencies involved in neurological health initiatives

Strengths and what to watch

Strengths

  • Demonstrated financial stability with five consecutive years of revenue growth and improving margins
  • Strong balance sheet with SEK 95.2 million in liquid funds as of Q1 2026
  • Established regulatory compliance track record with multiple SEC filings and public reporting

Watch for

  • Potential dilution from recent S-3 shelf registration indicating possible future equity offerings
  • Concentration risk in healthcare sector spending which may fluctuate with economic conditions
  • Intense competition in neurotechnology space from both startups and established medtech firms

Recent moves

Key Information

Founded
1988
Headquarters
Cedar Park, Texas

Frequently Asked Questions

What is NAMS Firefly and what do they do?

NAMS Firefly, operating as Firefly Neuroscience, develops AI-powered neurotechnology software for brain health monitoring and cognitive enhancement. The company rebranded from Wavedancer in 2024 and focuses on neurological applications, serving healthcare, research, and corporate wellness sectors with its AI-driven solutions.

How is Firefly Neuroscience performing financially?

Firefly Neuroscience shows steady growth, with SEK 503.2 million revenue in 2025 and SEK 112.2 million in Q1 2026. Operating margins improved from 9% to 13% (2012-2025), with SEK 95.2 million liquid funds. Recent SEC filings indicate ongoing capital-raising activities for future growth initiatives.

Who uses NAMS Firefly's neurotechnology?

NAMS Firefly serves healthcare providers needing diagnostic tools, research institutions studying brain disorders, corporate wellness programs enhancing employee cognition, and government health agencies. Their AI solutions address diverse neurological needs across these sectors, from clinical applications to performance optimization.

What makes Firefly Neuroscience's technology unique?

Firefly Neuroscience combines AI with neurotechnology for precise brain health monitoring and cognitive enhancement. Their software solutions stand out for clinical applications and wellness programs, backed by five years of revenue growth and substantial R&D investments from their strong financial position.

What recent developments has NAMS Firefly announced?

In May 2026, Firefly filed S-8 and S-3 SEC registrations for employee benefits and potential future offerings. Q1 2026 results showed SEK 112.2 million revenue with 10.6% operating margin. These moves signal growth plans while maintaining stable demand (SEK 111.3 million order book).

Are there risks to investing in neurotechnology like NAMS Firefly?

Potential risks include sector concentration in healthcare spending, competition from medtech firms, and possible share dilution from recent S-3 registration. However, Firefly's consistent revenue growth (SEK 302M to 503M 2021-2025) and SEK 95M liquidity provide financial stability buffers against these challenges.

Sources

  1. firefly.se — Financial performance metrics and growth trajectory
  2. www.sec.gov — Recent SEC filings and corporate actions
  3. www.sec.gov — Q1 2026 financial results
  4. www.sec.gov — Recent S-8 filing for employee benefit plans